• LAST PRICE
    0.2500
  • TODAY'S CHANGE (%)
    Trending Down-0.0005 (-0.1996%)
  • Bid / Lots
    0.2303/ 25
  • Ask / Lots
    0.2699/ 4
  • Open / Previous Close
    0.2536 / 0.2505
  • Day Range
    Low 0.2500
    High 0.2697
  • 52 Week Range
    Low 0.2300
    High 2.3800
  • Volume
    13,599
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 0.2505
TimeVolumeKRBP
10:29 ET1000.253649
10:44 ET32000.2697
12:10 ET30000.260051
01:13 ET20000.26
01:24 ET15000.2505
02:00 ET10000.26005
03:17 ET10000.25525
03:26 ET8700.253683
03:57 ET1000.25
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesKRBP
Kiromic Biopharma Inc
4.6M
-0.1x
---
United StatesRGMP
Regnum Corp
4.6M
-5.0x
---
United StatesFWBI
First Wave BioPharma Inc
4.6M
0.0x
---
United StatesONCS
OncoSec Medical Inc
4.6M
-0.1x
---
United StatesFNAM
Evolutionary Genomics Inc
4.7M
-1.7x
---
United StatesSCPS
Scopus Biopharma Inc
4.5M
-0.3x
---
As of 2022-12-06

Company Information

Kiromic BioPharma, Inc. is an artificial intelligence (AI) driven, end-to-end allogenic cell therapy company. The Company is engaged in developing the multi-indication allogeneic T cell therapy that exploits the natural potency of the Gamma Delta T cell (GDT) to target solid tumors. The Procel, Isocel, and Deltacel product platform candidates consist of allogeneic cell therapy candidates that are in the preclinical development stage. Its Procel product candidate consists of engineered GDTs targeting PD-L1. Its Isocel product candidate consists of engineered GDTs targeting Mesothelin Isoform 2 positive tumors (Iso-Meso). Its Deltacel product candidate consists of non-engineered GDTs used to treat solid tumors. Its Allogenic Lead Exogenous Isoforms (ALEXIS)-PRO-1 trial candidate is its allogeneic GDT therapy product targeting PD-L1. Its ALEXIS-ISO-1 trial candidate is its allogenic GDT therapy product targeting an isoform of Mesothelin that is present in tumor cells, namely Isomeso.

Contact Information

Headquarters
7707 Fannin St., Suite 140HOUSTON, TX, United States 77054
Phone
832-968-4888
Fax
302-655-5049

Executives

No data available

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$4.6M
Revenue (TTM)
$0.00
Shares Outstanding
18.2M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
---
EPS
$-2.11
Book Value
$1.76
P/E Ratio
-0.1x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.